Titlebook: p53 in the Clinics; Pierre Hainaut,Magali Olivier,Klas G. Wiman Book 2013 Springer Science+Business Media New York 2013 TP53.cancer resear

只看該作者 · 發(fā)表于 2025-3-25 10:30:13

Designing p53 Trials: A Surgical Oncologists View,ement among experts as to how new anticancer drugs should be evaluated before they can be used in standard therapy. However, a corresponding algorithm for the clinical implementation of markers does not exist..Before designing a phase III marker trial one must know whether the marker being tested pr

只看該作者 · 發(fā)表于 2025-3-25 11:39:08

只看該作者 · 發(fā)表于 2025-3-25 16:22:29

只看該作者 · 發(fā)表于 2025-3-25 22:20:15

, Somatic Mutations: Prognostic and Predictive Value in Human Cancers,edictive value of TP53 mutation status in cancer patients. Despite many studies showing a poor prognosis associated with TP53-mutated status, no consensus results have been produced that could support clinical applications. Here, we review these studies, in particular those performed in the context of specific treatment regimen.

只看該作者 · 發(fā)表于 2025-3-26 00:21:16

只看該作者 · 發(fā)表于 2025-3-26 08:14:51

只看該作者 · 發(fā)表于 2025-3-26 12:15:04

Designing p53 Trials: A Surgical Oncologists View,wledge of the underlying scenario is a prerequisite to decide on the optimal marker trial design..We describe a generally applicable algorithm for clinical evaluation of a marker. The algorithm is applied to current knowledge concerning the marker p53.

只看該作者 · 發(fā)表于 2025-3-26 15:52:26

只看該作者 · 發(fā)表于 2025-3-26 19:27:56

		自動(dòng)登錄	找回密碼
密碼			To register

關(guān)于派博傳思			派博傳思旗下網(wǎng)站			友情鏈接
派博傳思介紹	公司地理位置	論文服務(wù)流程	影響因子官網(wǎng)	吾愛論文網(wǎng)	大講堂	北京大學(xué)	Oxford Uni.	Harvard Uni.
發(fā)展歷史沿革	期刊點(diǎn)評	投稿經(jīng)驗(yàn)總結(jié)	SCIENCEGARD	IMPACTFACTOR	派博系數(shù)	清華大學(xué)	Yale Uni.	Stanford Uni.
\|Archiver\|手機(jī)版\|小黑屋\| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-7 02:02
Copyright © 2001-2015 派博傳思京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved